40 min

Innovative Ideas to Transform New Medication Launches: A Case Study and Panel Discussion OptimizeRx - Learning Together: Navigating the COVID-19 Pandemic

    • Life Sciences

Launching a new medication in a complex disease state is fraught with complications that can impact medication adherence. New medications that can greatly improve a patient’s quality of life and overall health can present significant side effects that often lead patients to abandon treatment. When patients are faced with a life-threatening disease, unexpected or misunderstood side effects from medication can trigger fear that the medication is having an adverse effect, or worsening their condition.

In this webinar, we’ll discuss innovative and best-in-practice approaches to new drug launches that explore the art, science, and psychology to treatment and medication adherence. Join this incredible panel of industry experts and thought leaders with decades of experience in innovative drug launches. We’ll explore the complexities and opportunities for life science companies to deliver new programs that achieve positive outcomes – for patients and their care teams.

During this webinar our panelists will review a special case study of a highly successful patient engagement program that combined nurse support with text-based communication, leading to over 34% engagement and averaging 14 minutes per session. This innovative program helped patients successfully navigate the side effects of treatment and stay adherent on life-extending therapy. The industry benchmarks for patient engagement and adherence are being redefined by such programs.

Guests:


Eugene Borukhovich, Chairman & COO: YourCoach.Health, former Global Head Digital Health, Bayer
Chris DiCostanzo, Vice President, Client Relations, OptimizeRx
Mary Anne Greenberg, CEO, Diligent Health Solutions

Moderated by Rebecca Love, MSN, RN, Principal, Clinical Innovations, OptimizeRx and Mark Bard, Co-Founder, The DHC Group
Send your questions to webinars@optimizerx.com 

Visit www.OptimizeRx.com/webinars for more insightful industry conversations. 

Follow us on Twitter and LinkedIn

Launching a new medication in a complex disease state is fraught with complications that can impact medication adherence. New medications that can greatly improve a patient’s quality of life and overall health can present significant side effects that often lead patients to abandon treatment. When patients are faced with a life-threatening disease, unexpected or misunderstood side effects from medication can trigger fear that the medication is having an adverse effect, or worsening their condition.

In this webinar, we’ll discuss innovative and best-in-practice approaches to new drug launches that explore the art, science, and psychology to treatment and medication adherence. Join this incredible panel of industry experts and thought leaders with decades of experience in innovative drug launches. We’ll explore the complexities and opportunities for life science companies to deliver new programs that achieve positive outcomes – for patients and their care teams.

During this webinar our panelists will review a special case study of a highly successful patient engagement program that combined nurse support with text-based communication, leading to over 34% engagement and averaging 14 minutes per session. This innovative program helped patients successfully navigate the side effects of treatment and stay adherent on life-extending therapy. The industry benchmarks for patient engagement and adherence are being redefined by such programs.

Guests:


Eugene Borukhovich, Chairman & COO: YourCoach.Health, former Global Head Digital Health, Bayer
Chris DiCostanzo, Vice President, Client Relations, OptimizeRx
Mary Anne Greenberg, CEO, Diligent Health Solutions

Moderated by Rebecca Love, MSN, RN, Principal, Clinical Innovations, OptimizeRx and Mark Bard, Co-Founder, The DHC Group
Send your questions to webinars@optimizerx.com 

Visit www.OptimizeRx.com/webinars for more insightful industry conversations. 

Follow us on Twitter and LinkedIn

40 min